NEW YORK, May 11, 2022 /PRNewswire/ — AiTA Bio, a New York-based bio-MEMS company, today announced it has secured $8.5 million in Series A funding led by Hammerstone Capital, BlackPoint Partners, SkyView Investment Advisors, and others. AiTA is developing an integrated…
Innovative Drug Delivery Company Partners with Fortune 100 Global Foundry for Next-Generation Artificial Pancreas
